Scroll to top

Archive

CLINUVEL
Posted by CLINUVEL
February 10, 2020

Request for FDA Guidance Meeting SCENESSE® in Vitiligo

CLINUVEL requests Type C Guidance meeting to progress the clinical program in...

Read More
CLINUVEL
Posted by CLINUVEL
February 3, 2020

Australian TGA commences SCENESSE® review

EXECUTIVE SUMMARY SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare...

Read More
CLINUVEL
Posted by CLINUVEL
January 31, 2020

Appendix 4C

CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering...

Read More
CLINUVEL
Posted by CLINUVEL
January 29, 2020

CLINUVEL Kommuniqué I

Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde Im Namen des CLINUVEL-Ausschusses wünsche...

Read More
CLINUVEL
Posted by CLINUVEL
January 16, 2020

CLINUVEL Newsletter

Dear shareholders, friends On behalf of the CLINUVEL Board, I wish you...

Read More
CLINUVEL
Posted by CLINUVEL
December 23, 2019

SCENESSE® registration dossier submitted in Australia

CLINUVEL initiates the registration process under priority review for its new pharmaceutical...

Read More
CLINUVEL
Posted by CLINUVEL
December 10, 2019

Notice of Change of Interests of Substantial Holder

  Form 604 – Notice of change of interests of substantial holder...

Read More
CLINUVEL
Posted by CLINUVEL
December 9, 2019

Change of Director's Interest Notice

Appendix 3Y – Change of Director’s Interest Notice, is available to download.

Read More
CLINUVEL
Posted by CLINUVEL
December 6, 2019

Lapse and Forfeit of Unlisted Conditional Performance Rights

CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...

Read More
CLINUVEL
Posted by CLINUVEL
December 5, 2019

Changes of Director's Interest Notice

Appendix 3Y Change of Director’s Interest Notice Download PDF

Read More
CLINUVEL
Posted by CLINUVEL
December 5, 2019

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement. Download...

Read More
CLINUVEL
Posted by CLINUVEL
December 5, 2019

Changes in Composition to Committeess

CLINUVEL PHARMACEUTICALS LTD today announced changes to the composition of its Audit...

Read More
CLINUVEL
Posted by CLINUVEL
December 2, 2019

CEO Letter

  Dear shareholders,   On 8 October 2019, CLINUVEL obtained its first...

Read More
CLINUVEL
Posted by CLINUVEL
November 26, 2019

Appendix 3X

Initial Director’s Interest Notice. Download PDF

Read More
CLINUVEL
Posted by CLINUVEL
November 26, 2019

CLINUVEL Appoints Non-Executive Director

CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Professor Jeffrey Rosenfeld as...

Read More
CLINUVEL
Posted by CLINUVEL
November 20, 2019

Chair’s Address to the Annual General Meeting

Melbourne, Australia, 20 November 2019 A MOMENTOUS ACHIEVEMENT Looking at the year...

Read More
We use cookies to give you the best experience.